the formation of neurotoxic structures (oligomers of amyloid proteins) responsible for these two neurodegenerative diseases (new therapeutic target, the only molecule in the world capable of acting on Alzheimer's and Parkinson's).

Their drug candidate is thus the first representative of a new therapeutic class that inhibits a fundamental mechanism common to Alzheimer's and Parkinson's diseases.